Chemoinformaics analysis of Hippeastrine N-oxide
| Molecular Weight | 331.324 | nRot | 0 |
| Heavy Atom Molecular Weight | 314.188 | nRig | 25 |
| Exact Molecular Weight | 331.106 | nRing | 5 |
| Solubility: LogS | -1.159 | nHRing | 3 |
| Solubility: LogP | 0.091 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 41 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 24 | No. of Aromatic Carbocycles | 1 |
| nHetero | 7 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 17 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 17 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 6 | No. of Arom Bond | 6 |
| nHA | 6 | APOL | 45.6375 |
| nHD | 1 | BPOL | 25.1385 |
| QED | 0.331 |
| Synth | 4.785 |
| Natural Product Likeliness | 2.217 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0.998 |
| HIA | 0.948 |
| CACO-2 | -5.551 |
| MDCK | 0.000101717 |
| BBB | 0.547 |
| PPB | 0.374897 |
| VDSS | 2.272 |
| FU | 0.718686 |
| CYP1A2-inh | 0.118 |
| CYP1A2-sub | 0.704 |
| CYP2c19-inh | 0.038 |
| CYP2c19-sub | 0.53 |
| CYP2c9-inh | 0.01 |
| CYP2c9-sub | 0.476 |
| CYP2d6-inh | 0.089 |
| CYP2d6-sub | 0.243 |
| CYP3a4-inh | 0.151 |
| CYP3a4-sub | 0.276 |
| CL | 13.863 |
| T12 | 0.953 |
| hERG | 0.006 |
| Ames | 0.007 |
| ROA | 0.804 |
| SkinSen | 0.035 |
| Carcinogencity | 0.927 |
| EI | 0.028 |
| Respiratory | 0.312 |
| NR-Aromatase | 0.002 |
| Antiviral | Yes |
| Prediction | 0.72303 |